Prostatype Genomics AB (SE:PROGEN)
:PROGEN
PROGEN Stock Chart & Stats
kr0.75
-kr0.32(-6.69%)
At close: 4:00 PM EST
kr0.75
-kr0.32(-6.69%)
Day’s Range― - ―
52-Week Rangekr0.28 - kr3.56
Previous CloseN/A
Volume7.01K
Average Volume (3M)300.11K
Market Cap
kr57.77M
Enterprise Valuekr23.14M
Total Cash (Recent Filing)kr12.93M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.41
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding59,189,320
10 Day Avg. Volume460,844
30 Day Avg. Volume300,114
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)kr1.23M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityNear-zero debt materially reduces financial distress risk and provides structural flexibility for a small diagnostics company. Over a 2–6 month horizon this helps preserve runway, enables choice between equity or project financing, and supports continued commercialization efforts without heavy interest burdens.
Focused, Clinical-Grade Diagnostic ProductA focused proprietary diagnostic (Prostatype) with combined biomarker and clinical inputs is a durable competitive asset. Clinical decision-support tests have sticky demand, recurring per-test revenue via labs/providers, and clear clinical utility in prostate cancer, supporting long-term market positioning and commercialization scalability.
Improving Cash Burn TrendA material reduction in cash burn year-over-year signals operational progress and tighter cost management. If sustained, this structural improvement extends runway, reduces near-term financing needs, and increases the chance revenues or partnerships can bridge to break-even within several quarters.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow shows the business is not self-financing and remains reliant on external funding. Over months this constrains investment in sales, lab capacity and regulatory activities, raising dilution or execution risk if capital markets tighten or partners delay commitments.
Small, Volatile And Declining RevenueVery small, inconsistent revenue undermines economies of scale necessary for diagnostics commercialization. A ~17% decline in 2025 versus 2024 indicates fragile adoption and raises the time and capital required to achieve sustainable volumes and margin support for long-term profitability.
Deep And Persistent LossesSeverely negative margins (net margin ~-75% in 2025) reflect a cost base far exceeding current revenues. Persisting large losses will erode equity, demand repeated funding rounds, and limit ability to reinvest in commercialization or R&D unless material revenue growth or cost restructuring occurs.
PROGEN FAQ
What was Prostatype Genomics AB’s price range in the past 12 months?
Prostatype Genomics AB lowest stock price was kr0.28 and its highest was kr3.56 in the past 12 months.
What is Prostatype Genomics AB’s market cap?
Prostatype Genomics AB’s market cap is kr57.77M.
When is Prostatype Genomics AB’s upcoming earnings report date?
Prostatype Genomics AB’s upcoming earnings report date is Aug 13, 2026 which is in 137 days.
How were Prostatype Genomics AB’s earnings last quarter?
Prostatype Genomics AB released its earnings results on Feb 26, 2026. The company reported -kr0.397 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.397.
Is Prostatype Genomics AB overvalued?
According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued.
Does Prostatype Genomics AB pay dividends?
Prostatype Genomics AB does not currently pay dividends.
What is Prostatype Genomics AB’s EPS estimate?
Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prostatype Genomics AB have?
Prostatype Genomics AB has 59,189,320 shares outstanding.
What happened to Prostatype Genomics AB’s price movement after its last earnings report?
Prostatype Genomics AB reported an EPS of -kr0.397 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.907%.
Which hedge fund is a major shareholder of Prostatype Genomics AB?
Currently, no hedge funds are holding shares in SE:PROGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prostatype Genomics AB
Prostatype Genomics AB (PROGEN) is a biotechnology company specializing in the development of genomic tests aimed at improving the diagnosis and treatment of prostate cancer. The company operates in the healthcare sector, focusing on precision medicine by providing innovative genomic solutions that help clinicians make informed decisions regarding patient management and personalized treatment plans. PROGEN's core product is its proprietary genomic test, which analyzes tumor characteristics to predict disease progression and guide therapeutic choices for prostate cancer patients.